The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof.

##STR00001##

wherein R.sub.1 is C(O)O-alkyl, carbonate ester, or C(O)-alkyl, ester, or C(O)N-alkyl, carbamate ester and wherein R.sub.2 is CH3 or CD.sub.3. The alkyl ester can contain saturated or unsaturated C.sub.12 to C.sub.26 alkyl carbon. The alkyl carbon chain can have either a straight, branched, noncyclic, cyclic, unsubstituted or substituted structure.

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

The invention provides (+)--dihydrotetrabenazine succinate salt.

Also provided are (+)--dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)--dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)--dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome.

The invention further provides a method for preparing the (+)--dihydrotetrabenazine succinate salt.

The invention provides (+)--dihydrotetrabenazine succinate salt.

Also provided are (+)--dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)--dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)--dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome.

The invention further provides a method for preparing the (+)--dihydrotetrabenazine succinate salt.

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)--3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.

Compositions containing the compound of general formula I: ##STR00001##
are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.

Compositions containing the compound of general formula I: ##STR00001##
are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.

The disclosure includes compounds of Formula (I)

##STR00001## wherein Z.sub.1, Z.sub.2, Z.sub.3, X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are defined herein. Also disclosed is a method for treating HBV infection.

The disclosure includes compounds of Formula (I)

##STR00001## wherein Z.sub.1, Z.sub.2, Z.sub.3, X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are defined herein. Also disclosed is a method for treating HBV infection.